Under the terms of the agreement, Ocugen will have US rights to the vaccine candidate and will be responsible for clinical development, regulatory approval including emergency use approval (EUA) and commercialization for the US market. Bharat Biotech will supply initial doses to be used in the US upon Ocugen’s receipt of an EUA.from Moneycontrol Business News https://ift.tt/2MkGrVx
No comments:
Post a Comment